National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting, 16218 [2022-05966]

Download as PDF 16218 ACTION: Federal Register / Vol. 87, No. 55 / Tuesday, March 22, 2022 / Notices Notice; correction. The Food and Drug Administration (FDA) is correcting a notice entitled ‘‘Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry’’ that appeared in the Federal Register of March 10, 2022. The document omitted the date by which comments on the draft guidance should be submitted to FDA. This error is corrected in this document for clarity. FOR FURTHER INFORMATION CONTACT: Sarah Venti, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 301–796–3130, drugtrackandtrace@ fda.hhs.gov. SUPPLEMENTARY INFORMATION: In the Federal Register of March 10, 2022 (87 FR 13738), appearing on page 13738, in FR Doc. 2022–05018, in the second column, the DATES section is corrected to read as follows: DATES: The announcement of the guidance is published in the Federal Register on March 10, 2022. Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by May 9, 2022. SUMMARY: Dated: March 17, 2022. Andi Lipstein Fristedt, Deputy Commissioner for Policy, Legislation, and International Affairs, U.S. Food and Drug Administration. [FR Doc. 2022–06006 Filed 3–21–22; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health lotter on DSK11XQN23PROD with NOTICES1 National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, March 23, 2022, 09:00 a.m. to March 24, 2022, 04:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the Federal Register on February 25, 2022, 308582. Dr. Kozel wants to change the date for his meeting. The meeting is closed to the public. VerDate Sep<11>2014 18:24 Mar 21, 2022 Jkt 256001 Dated: March 16, 2022. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2022–05966 Filed 3–21–22; 8:45 am] Center for Scientific Review; Amended Notice of Meeting BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Microbiology, Infectious Diseases and AIDS Initial Review Group; Acquired Immunodeficiency Syndrome Research Study Section; Acquired Immunodeficiency Syndrome Research Study Section (AIDS). Date: April 20, 2022. Time: 10:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F40A, Rockville, MD 20892 (Virtual Meeting). Contact Person: Dimitrios Nikolaos Vatakis, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, MSC– 9823, Bethesda, MD 20892, (301) 761–7176, dimitrios.vatakis@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: March 16, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–05968 Filed 3–21–22; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 National Institutes of Health Notice is hereby given of a change in the meeting of the Sleep Disorders Research Advisory Board, April 7, 2022, 12:00 p.m. to 5:00 p.m., Virtual Meeting, which was published in the Federal Register on March 09, 2022, V 87 Vol. 46, Page 13302, FR Doc No. 2022– 04982. Meeting is being amended to change the telephone call in number to 1–669– 254–5252 (Meeting ID: 161 532 8417 Passcode: 330488). The meeting is open to the public. Dated: March 16, 2022. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–05969 Filed 3–21–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Clinical Trials and Comparative Effectiveness Studies in Neurology. Date: March 28–29, 2022. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Shanta Rajaram, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, E:\FR\FM\22MRN1.SGM 22MRN1

Agencies

[Federal Register Volume 87, Number 55 (Tuesday, March 22, 2022)]
[Notices]
[Page 16218]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-05966]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the National 
Institute of Diabetes and Digestive and Kidney Diseases Special 
Emphasis Panel, March 23, 2022, 09:00 a.m. to March 24, 2022, 04:00 
p.m., National Institutes of Health, Rockledge II, 6701 Rockledge 
Drive, Bethesda, MD, 20892 which was published in the Federal Register 
on February 25, 2022, 308582.
    Dr. Kozel wants to change the date for his meeting. The meeting is 
closed to the public.

    Dated: March 16, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-05966 Filed 3-21-22; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.